{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:54:51Z","timestamp":1791924891265,"version":"4.3.4"},"reference-count":29,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100017639","name":"Entasis Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017639","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,9,20]]},"abstract":"<jats:p>\n            Sulbactam-durlobactam is a \u03b2-lactam-\u03b2-lactamase inhibitor combination designed to treat serious\n            <jats:named-content content-type=\"genus-species\">Acinetobacter baumannii<\/jats:named-content>\n            <jats:italic>-calcoaceticus<\/jats:italic>\n            complex (ABC) infections, including carbapenem-non-susceptible and multidrug-resistant (MDR) isolates. The current study characterized the\n            <jats:italic>in vitro<\/jats:italic>\n            activity of sulbactam-durlobactam against a collection of 5,032 ABC clinical isolates collected in 33 countries across the Asia\/South Pacific region, Europe, Latin America, the Middle East, and North America from 2016 to 2021.\n          <\/jats:p>","DOI":"10.1128\/aac.00781-22","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T13:00:41Z","timestamp":1661432441000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":109,"title":["<i>In Vitro<\/i>\n            Activity of Sulbactam-Durlobactam against Global Isolates of\n            <i>Acinetobacter baumannii<\/i>\n            -\n            <i>calcoaceticus<\/i>\n            Complex Collected from 2016 to 2021"],"prefix":"10.1128","volume":"66","author":[{"given":"James A.","family":"Karlowsky","sequence":"first","affiliation":[{"name":"IHMA, Inc., Schaumburg, Illinois, USA"},{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3339-2701","authenticated-orcid":true,"given":"Meredith A.","family":"Hackel","sequence":"additional","affiliation":[{"name":"IHMA, Inc., Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"McLeod","sequence":"additional","affiliation":[{"name":"Entasis Therapeutics, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7110-0493","authenticated-orcid":true,"given":"Alita A.","family":"Miller","sequence":"additional","affiliation":[{"name":"Entasis Therapeutics, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9030119"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00058-16"},{"key":"e_1_3_3_4_2","unstructured":"Kanafani ZA Kanj SS. 2022. Acinetobacter infection: treatment and prevention. Wolters Kluwer Alphen aan de Rijn The Netherlands.https:\/\/www.uptodate.com\/contents\/acinetobacter-infection-treatment-and-prevention. Accessed 1 March 2022."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy293"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.03.001"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30753-3"},{"key":"e_1_3_3_8_2","unstructured":"ClinicalTrials.gov. 2019. Study to evaluate the efficacy and safety of intravenous sulbactam-ETX2514 in the treatment of patients with infections caused by Acinetobacter baumannii-calcoaceticus complex (ATTACK). U.S. National Library of Medicine Bethesda MD.  https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03894046. Accessed 14 February 2022."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.709974"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04808-14"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2017.104"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00159-19"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02534-19"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa208"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2021.05.001"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.814530"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa119"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01990-21"},{"key":"e_1_3_3_19_2","volume-title":"Pharmacokinetics\/pharmacodynamics and phase 3 dose projection for the novel \u03b2-lactamase inhibitor ETX2514 in combination with sulbactam against Acinetobacter baumannii-calcoaceticus complex (ABC), poster AAR-LB-14.","author":"O\u2019Donnell J","year":"2019","unstructured":"O\u2019Donnell J, Rubino C, Onufrak NJ, Bhaunani SM, Ambrose PG, Tommasi R, Stone E, Rodvold K, Mueller J, Isaacs R, Miller A, Srinivasan S. 2019. Pharmacokinetics\/pharmacodynamics and phase 3 dose projection for the novel \u03b2-lactamase inhibitor ETX2514 in combination with sulbactam against Acinetobacter baumannii-calcoaceticus complex (ABC), poster AAR-LB-14. Microbe 2019, San Francisco, CA."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01089-18"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01110-18"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw353"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01699-19"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy378"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja208835z"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03938-14"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106345"},{"key":"e_1_3_3_28_2","volume-title":"Performance standards for antimicrobial susceptibility testing.","author":"Clinical and Laboratory Standards Institute","year":"2021","unstructured":"Clinical and Laboratory Standards Institute. 2021. Performance standards for antimicrobial susceptibility testing. M100, 31st ed. CLSI, Wayne, PA.","edition":"31"},{"key":"e_1_3_3_29_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically.","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M07-A11, 11th ed. CLSI, Wayne, PA.","edition":"11"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00781-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00781-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T13:12:57Z","timestamp":1663679577000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00781-22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,20]]}},"alternative-id":["10.1128\/aac.00781-22"],"URL":"https:\/\/doi.org\/10.1128\/aac.00781-22","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]},"assertion":[{"value":"2022-06-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00781-22"}}